tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Allogene Therapeutics price target lowered to $4 from $8 at Citi
PremiumThe FlyAllogene Therapeutics price target lowered to $4 from $8 at Citi
2M ago
Allogene Therapeutics: Strategic Cash Management and ALPHA3 Potential Drive Buy Rating Amid Clinical Delays
Premium
Ratings
Allogene Therapeutics: Strategic Cash Management and ALPHA3 Potential Drive Buy Rating Amid Clinical Delays
2M ago
Allogene Therapeutics price target lowered to $10 from $14 at Truist
Premium
The Fly
Allogene Therapeutics price target lowered to $10 from $14 at Truist
2M ago
Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential
PremiumRatingsPositive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential
2M ago
Allogene downgraded to Market Perform from Outperform at Citizens JMP
Premium
The Fly
Allogene downgraded to Market Perform from Outperform at Citizens JMP
2M ago
Allogene Therapeutics Advances Clinical Trials and Extends Cash Runway
Premium
Company Announcements
Allogene Therapeutics Advances Clinical Trials and Extends Cash Runway
2M ago
Allogene Therapeutics participates in a conference call with JPMorgan
PremiumThe FlyAllogene Therapeutics participates in a conference call with JPMorgan
4M ago
Allogene Therapeutics: Buy Rating Backed by Promising Pipeline Developments and Strong Financial Position
Premium
Ratings
Allogene Therapeutics: Buy Rating Backed by Promising Pipeline Developments and Strong Financial Position
4M ago
Allogene Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
Premium
The Fly
Allogene Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100